Economics of Antibody Drug Conjugates (ADCs): Innovation, Investment and Market Dynamics

Bhushan, Arya; Misra, Preeti

doi:10.1007/s11912-024-01582-x

Curr Oncol Rep

2024

DOI: 10.1007/s11912-024-01582-x

|View full text |Cite

Economics of Antibody Drug Conjugates (ADCs): Innovation, Investment and Market Dynamics

Arya Bhushan,

Preeti Misra

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis

Chen,

He,

Huang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

IntroductionAntibody-drug conjugates (ADCs) are increasingly utilized in patients with solid tumors and hematologic malignancies. However, the adverse ocular toxicity induced by ADCs has not been comprehensively evaluated in real-world clinical settings.MethodsData from April 2019 to March 2024 based on the FDA Adverse Event Reporting System (FAERS) were extracted and analyzed. Disproportionality analysis was used to evaluate the association between ADCs and ocular adverse events (AEs). The median time to onset (TTO) of various ADCs was compared.ResultsA comprehensive analysis identified 2,686 ocular AEs associated with ADCs. Among these, Tisotumab vedotin had the most positive signals at the preferred terms (PTs) level, followed by trastuzumab emtansine and enfortumab vedotin. In contrast, gemtuzumab ozogamicin demonstrated minimal ocular toxicity signals. Cluster analysis revealed that ADC-related ocular toxicities predominantly manifested as corneal disorders or ocular neuromuscular disorders. The median onset of ocular toxicity varied considerably, with enfortumab vedotin showing the earliest median onset at 12.5 days.ConclusionsOur study demonstrates the association between ADCs and ocular AEs based on real-world data, providing valuable guidance for clinicians when prescribing ADCs. And we found some important safety signals that have not been mentioned in the label or previous studies.

show abstract

Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis

Chen,

He,

Huang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Economics of Antibody Drug Conjugates (ADCs): Innovation, Investment and Market Dynamics

Cited by 1 publication

References 45 publications

Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis

Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis

Contact Info

Product

Resources

About